Find clinical trials for Melanoma in Baltimore, MD
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Melanoma trials near Baltimore, MD, USA:
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
Bethesda, Maryland, United States and 32 other locations
(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...
Phase 3
Baltimore, Maryland, United States and 105 other locations
assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma...
Phase 3
Baltimore, Maryland, United States and 84 other locations
of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma...
Phase 1, Phase 2
Fairfax, Virginia, United States and 24 other locations
of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...
Phase 2
Lutherville-Timonium, Maryland, United States and 63 other locations
patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent...
Phase 2
Fairfax, Virginia, United States and 52 other locations
treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metas...
Phase 2
Washington, District of Columbia, United States and 5 other locations
to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...
Phase 3
Washington, District of Columbia, United States and 171 other locations
(Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma...
Phase 3
Lutherville, Maryland, United States and 178 other locations
Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.Part 2 is phase II design of APG-115 at recommended phase 2...
Phase 1, Phase 2
Washington, District of Columbia, United States and 19 other locations
Clinical trials
Research sites
Resources
Legal